In August, the insulin management software company Glytec unveiled the latest version of its Glucommander insulin dosing software to make it easier for providers, nurses, and pharmacists to offer optimal, personalized care. More than 300 hospitals in the U.S. use Glytec’s eGlycemic Management System® (eGMS®) for glycemic management for their patients. Glytec chief medical officer...
A new book spotlights athletes thriving with diabetes. In the new book, Winning with Diabetes: Inspiring Stories from Athletes to Help You Thrive, Rita R. Kalyani, MD, MHS; Mark D. Corriere, MD; and Patrick Smith have created an inspirational handbook that clinicians can share with their patients to help them overcome the challenges they may...
Aside from a litany of cultural and clinical barriers many Hispanics face in getting proper healthcare, supply and demand has proven difficult with certain medications, most recently tirzepatide. Rodolfo Galindo, MD, discusses these issues as well as why clinicians must often go “beyond the guidelines” when treating specific patient populations. In 2023, Hispanics represent the...
The U.S. Food and Drug Administration (FDA) last month approved a new indication for somapacitan-beco injection 5 mg, 10 mg, or 15 mg for the treatment of children aged 2.5 years and older who have growth failure due to inadequate secretion of endogenous growth hormone. Novo Nordisk is marketing the treatment as Sogroya® The FDA approval...
Abbott announced that the U.S. Food and Drug Administration (FDA) has cleared a reader for its FreeStyle Libre® 3 integrated continuous glucose monitoring (iCGM) system, which features the world’s smallest, thinnest, and most discreet glucose sensor. With the FDA’s clearance of a standalone reader, Abbott is working to get the FreeStyle Libre 3 system added to Medicare’s...
Recent insulin price cuts are a dose of good news. In March, Eli Lilly lowered the price on its most popular insulins, with Novo Nordisk and Sanofi following suit shortly thereafter, but only after the $35 monthly price cap for people on Medicare that was mandated by the Inflation Reduction Act. Is this the...
Bigfoot Biomedical today announced the U.S. Food and Drug Administration (FDA) has issued 510(k) clearance for the Android version of the Bigfoot Unity® Mobile App, a necessary component of the Bigfoot Unity® Diabetes Management System. Given that 41 percent of U.S. smartphone users choose Android devices, this clearance enables expanded access to a large group...
[Ed. note: This post has been updated with a comment from Leonard C. Glass, MD, FACE, senior vice president, Lilly Diabetes and Obesity, Global Medical Affairs, Eli Lilly and Company] Eli Lilly and Company today announced price reductions of 70% for its most commonly prescribed insulins and an expansion of its Insulin Value Program that caps...